Related Experiment Videos
Ketorolac in reflex sympathetic dystrophy
1Department of Psychiatry, Bowman Gray School of Medicine, Winston-Salem, North Carolina 27157.
Clinical Neuropharmacology
|February 1, 1993
Summary
Intramuscular ketorolac offers a promising alternative for managing treatment-resistant reflex sympathetic dystrophy (RSD) pain. This approach shows marked improvement, addressing limitations of existing surgical and pharmacotherapy options for RSD patients.
Area of Science:
- Pain Management
- Neurology
- Pharmacology
Background:
- Reflex sympathetic dystrophy (RSD) treatment traditionally relies on surgical interventions like sympathetic blockade or sympathectomy.
- Pharmacological alternatives, including corticosteroids and antidepressants, have limitations due to side effects and patient non-response.
- Intravenous regional block (IVRB) with ketorolac has shown efficacy but presents challenges for outpatient settings.
Observation:
- A case study explored the efficacy of intramuscular ketorolac in a patient with treatment-resistant RSD.
- The patient experienced significant pain relief following intramuscular administration of ketorolac.
Findings:
- Intramuscular ketorolac demonstrated marked improvement in managing severe, treatment-resistant RSD pain.
- This route of administration bypasses the limitations associated with IVRB in outpatient scenarios.
Implications:
- Intramuscular ketorolac presents a viable, accessible alternative for RSD pain management, particularly in non-hospital settings.
- Further research into this administration route could expand treatment options for refractory RSD cases.
- This finding may offer relief for patients unresponsive to or experiencing side effects from conventional RSD therapies.